<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3514">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01371747</url>
  </required_header>
  <id_info>
    <org_study_id>RLY5016-205</org_study_id>
    <secondary_id>2011-000165-12</secondary_id>
    <nct_id>NCT01371747</nct_id>
  </id_info>
  <brief_title>Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)</brief_title>
  <acronym>AMETHYST-DN</acronym>
  <official_title>A Multicenter, Randomized, Open-Label, Dose Ranging Study to Evaluate the Efficacy and Safety of Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy Receiving Angiotensin-converting Enzyme Inhibitor (ACEI) and/or Angiotensin II Receptor Blocker (ARB) Drugs, With or Without Spironolactone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Relypsa, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Relypsa, Inc.</source>
  <oversight_info>
    <authority>Austria: Austrian Federal Office for Safety in Health Care</authority>
    <authority>Croatia: Ministry of Health and Social Welfare of the Republic of Croatia</authority>
    <authority>Georgia: Ministry of Health</authority>
    <authority>Hungary: National Institute of Pharmacy</authority>
    <authority>Serbia: Medicines and Medical Devices Agency of Serbia</authority>
    <authority>Slovenia: Agency for Medicinal products and Medical Devices</authority>
    <authority>Austria: Ethikkommission</authority>
    <authority>Croatia: Ethics Committee</authority>
    <authority>Hungary: Scientific and Medical Research Council Ethics Committee</authority>
    <authority>Serbia: Ethics Committee</authority>
    <authority>Slovenia: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study determined the optimal starting dose of patiromer in treating hyperkalemia in
      participants with hypertension and diabetic nephropathy receiving ACEI and/or ARB drugs,
      with or without spironolactone. This study also evaluated the efficacy and safety of
      patiromer and the long term use of patiromer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RLY5016-205 was an open-label, randomized, dose ranging study to determine the optimal
      starting dose, efficacy and safety of patiromer in treating hyperkalemia in hypertensive
      patients with nephropathy due to type 2 diabetes mellitus (T2DM) receiving
      Angiotensin-converting Enzyme Inhibitor (ACEI) and/or Angiotensin II Receptor Blocker (ARB)
      drugs, with or without spironolactone.

      The study consisted of the following periods:

        -  Screening: Up to 10 days (1 visit)

        -  Run-in for those who were not hyperkalemic at screening (Cohorts 1 and 2): up to 4
           weeks (1 to 4 visits)

        -  Patiromer Treatment Initiation: first 8 weeks of patiromer treatment (a minimum of 10
           visits)

        -  Patiromer Long-Term Maintenance: additional 44 weeks of patiromer treatment up to a
           total of one year (minimum of 11 additional visits)

        -  Follow-up (after patiromer discontinuation): 1 week (2 visits) OR 4 weeks (5 visits)
           depending on the final serum potassium level
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Mean Change in Serum Potassium From Baseline to Week 4 or Time of First Titration for Each Individual Starting Dose Group</measure>
    <time_frame>Baseline to Week 4 or First Titration</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Serum Potassium From Baseline to Week 8 or Time of First Titration for Each Individual Starting Dose Group</measure>
    <time_frame>Baseline to Week 8 or First Titration</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Serum Potassium From Baseline to Day 3 During the Treatment Initiation Period for Each Individual Starting Dose Group</measure>
    <time_frame>Baseline to Day 3</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Serum Potassium From Baseline to Week 52 During the Long-term Maintenance Period for Each Individual Starting Dose Group</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Serum Potassium From End of Treatment to Follow-up Visits Plus 7 Days</measure>
    <time_frame>End of Treatment to Following up Visit Plus 7 Days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving Serum Potassium Levels Within 3.5 to 5.5 mEq/L at Week 8 for Each Individual Starting Dose Group</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Achieving Serum Potassium Levels Within 4.0 to 5.0 mEq/L at Week 8 for Each Individual Starting Dose Group</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Serum Potassium Measurement of 4.0 - 5.0 mEq/L During Treatment Initiation Period for Each Individual Starting Dose Group</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportions of Participants Achieving Serum Potassium Levels Within 3.8 to 5.0 mEq/L at Week 52 for Each Individual Starting Dose Group</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">324</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Hypertension</condition>
  <condition>Hyperkalemia</condition>
  <arm_group>
    <arm_group_label>Stratum 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with baseline serum potassium &gt; 5.0 - 5.5 mEq/L (milliequivalent)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stratum 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with baseline serum potassium &gt; 5.5 - &lt; 6.0 mEq/L</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>patiromer</intervention_name>
    <description>Patiromer starting dose: 8.4 g/day, 16.8 g/day, and 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response.</description>
    <arm_group_label>Stratum 1</arm_group_label>
    <other_name>RLY5016 for Oral Suspension</other_name>
    <other_name>Veltassa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>patiromer</intervention_name>
    <description>Patiromer starting dose: 16.8 g/day, 25.2 g/day and 33.6 g/day, orally, as a divided dose, twice daily . The dose of patiromer could be titrated based on participant's serum potassium response.</description>
    <arm_group_label>Stratum 2</arm_group_label>
    <other_name>RLY5016 for Oral Suspension</other_name>
    <other_name>Veltassa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 30 - 80 years old at screening (S1)

          2. Type 2 diabetes mellitus (T2DM) diagnosed after age 30 which has been treated with
             oral medications or insulin for at least 1 year prior to S1

          3. Chronic kidney disease (CKD): estimated glomerular filtration rate (eGFR) 15 - &lt; 60
             mL/min/1.73m2 at screening based on central lab serum creatinine measurement (except
             for participants with hyperkalemia at S1), whose eligibility will be assessed based
             on local lab eGFR value)

          4. Urine albumin/creatinine ratio (ACR):

               1. Cohorts 1 and 2: urine ACR ≥ 30 mg/g at S1 AND average urine ACR ≥ 30 mg/g at
                  the beginning of Run-In Period (R0) based on up to three ACR values obtained
                  starting at S1 and ending at the R0 Visit

               2. Cohort 3: not applicable

          5. Local laboratory serum potassium (K+) values of:

               1. Cohorts 1 and 2: 4.3 - 5.0 mEq/L at S1; AND 4.5 - 5.0 mEq/L at R0; AND &gt; 5.0 - &lt;
                  6.0 mEq/L at randomization to patiromer (Baseline, T0 Visit)

               2. Cohort 3: &gt; 5.0 - &lt; 6.0 mEq/L at S1 OR at R0 after same day confirmation

          6. Must be receiving an ACEI and/or ARB for at least 28 days prior to screening

          7. Average systolic blood pressure (SBP) ≥ 130 - &lt; 180 mmHg AND average DBP ≥ 80 - &lt; 110
             mmHg (sitting) at both screening and R0 (as applicable)8. Females of child-bearing
             potential must be non-lactating, must have a negative serum pregnancy test at
             screening, and must have used a highly effective form of contraception for at least 3
             months before patiromer administration, during the study, and for one month after
             study completion

        9. Provide their written informed consent prior to participation in the study

        Exclusion Criteria:

          1. Type 1 diabetes mellitus

          2. Central lab hemoglobin A1c &gt; 12% at Screening 1 (S1) (except for Cohort 3
             participants who are hyperkalemic at S1)

          3. Emergency treatment for T2DM within the last 3 months

          4. A confirmed SBP &gt; 180 mmHg or diastolic blood pressure (DBP) &gt; 110 mmHg at any time
             during SI or Run-In Period or at Baseline T0 Visit

          5. Central lab serum magnesium &lt; 1.4 mg/dL (&lt; 0.58 mmol/L) at screening (Cohort 3
             participants will be evaluated based on local lab serum magnesium measurement)

          6. Central lab urine ACR ≥ 10000 mg/g at screening (except for Cohort 3 participants who
             are hyperkalemic at S1)

          7. Confirmed diagnosis or history of renal artery stenosis (unilateral or bilateral)

          8. Diabetic gastroparesis

          9. Non-diabetic chronic kidney disease

         10. History of bowel obstruction, swallowing disorders, severe gastrointestinal disorders
             or major gastrointestinal surgery (e.g., large bowel resection)

         11. Current diagnosis of NYHA (New York Heart Association) Class III or IV heart failure

         12. Body mass index (BMI) ≥ 40 kg/m2

         13. Any of the following events having occurred within 2 months prior to screening:
             unstable angina as judged by the Principal Investigator (PI), unresolved acute
             coronary syndrome, cardiac arrest or clinically significant ventricular arrhythmias,
             transient ischemic attack or stroke, use of any intravenous cardiac medication

         14. Prior kidney transplant, or anticipated need for transplant during study
             participation

         15. Active cancer, currently on cancer treatment or history of cancer in the past 2 years
             except for non-melanocytic skin cancer which is considered cured

         16. History of alcoholism or drug/chemical abuse within 1 year

         17. Central lab liver enzymes [alanine aminotransferase (ALT), aspartate aminotransferase
             (AST)] &gt; 3 times upper limit of normal at S1 (except for Cohort 3 patients with
             hyperkalemia at S1, who will have local lab ALT and AST)

         18. Loop and thiazide diuretics or other antihypertensive medications (calcium channel
             blocker, beta-blocker, alpha-blocker, or centrally acting agent) that have not been
             stable for at least 28 days prior to screening or not anticipated to remain stable
             during study participation

         19. Current use of polymer-based drugs (e.g., sevelamer, sodium polystyrene sulfonate,
             colesevelam, colestipol, cholestyramine), phosphate binders (e.g., lanthanum
             carbonate), or other potassium binders, or their anticipated need during study
             participation

         20. Current use of lithium

         21. Use of potassium sparing medications, including aldosterone antagonists (e.g.,
             spironolactone), drospirenone, potassium supplements, bicarbonate or baking soda in
             the last 7 days prior to screening

         22. Use of any investigational product within 30 days or 5 half-lives, whichever is
             longer, prior to screening

         23. Inability to consume the investigational product, or, in the opinion of the
             Investigator, inability to comply with the protocol

         24. In the opinion of the Investigator, any medical condition, uncontrolled systemic
             disease, or serious intercurrent illness that would significantly decrease study
             compliance or jeopardize the safety of the participant or affect the validity of the
             trial results
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Director Clinical Operations</last_name>
    <role>Study Director</role>
    <affiliation>Relypsa, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigator Site 201</name>
      <address>
        <city>Karlovac</city>
        <zip>47000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 207</name>
      <address>
        <city>Osijek</city>
        <zip>31000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 203</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 202</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 204</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 208</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 305</name>
      <address>
        <city>Tbilisi</city>
        <zip>0102</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 309</name>
      <address>
        <city>Tbilisi</city>
        <zip>0144</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator site 301</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 302</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 303</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 304</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 306</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 307</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 310</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 311</name>
      <address>
        <city>Tbilisi</city>
        <zip>0159</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 308</name>
      <address>
        <city>Tbilisi</city>
        <zip>0186</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 508</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 502</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 514</name>
      <address>
        <city>Budapest</city>
        <zip>H-1041</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 513</name>
      <address>
        <city>Budapest</city>
        <zip>H-1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 517</name>
      <address>
        <city>Budapest</city>
        <zip>H-1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 522</name>
      <address>
        <city>Gyor</city>
        <zip>H-9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 523</name>
      <address>
        <city>Hatvan</city>
        <zip>3000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 515</name>
      <address>
        <city>Jaszbereny</city>
        <zip>H-5100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 506</name>
      <address>
        <city>Kistarcsa</city>
        <zip>H-2143</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 503</name>
      <address>
        <city>Kisvarda</city>
        <zip>4600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 510</name>
      <address>
        <city>Mosonmagyarovar</city>
        <zip>H-9200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 504</name>
      <address>
        <city>Szekesfehervar</city>
        <zip>H-8000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 505</name>
      <address>
        <city>Szikszo</city>
        <zip>3800</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 507</name>
      <address>
        <city>Veszprem</city>
        <zip>H-8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 601</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 602</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 604</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 605</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 603</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 607</name>
      <address>
        <city>Zrenjanin</city>
        <zip>23000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 703</name>
      <address>
        <city>Celje</city>
        <zip>3000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 706</name>
      <address>
        <city>Golnik</city>
        <zip>4204</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 708</name>
      <address>
        <city>Jesenice</city>
        <zip>4270</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 701</name>
      <address>
        <city>Maribor</city>
        <zip>2000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 704</name>
      <address>
        <city>Slovenj Gradec</city>
        <zip>2380</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigator Site 707</name>
      <address>
        <city>Šempeter pri Gorici</city>
        <zip>5290</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Georgia</country>
    <country>Hungary</country>
    <country>Serbia</country>
    <country>Slovenia</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <link>
    <url>http://www.relypsa.com</url>
    <description>Relypsa company website</description>
  </link>
  <reference>
    <citation>Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA; AMETHYST-DN Investigators. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. JAMA. 2015 Jul 14;314(2):151-61. doi: 10.1001/jama.2015.7446. Erratum in: JAMA. 2015 Aug 18;314(7):731. Dosage error in article text.</citation>
    <PMID>26172895</PMID>
  </reference>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 11, 2015</lastchanged_date>
  <firstreceived_date>June 9, 2011</firstreceived_date>
  <firstreceived_results_date>November 11, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hyperkalemia</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Treatment of Hyperkalemia</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Diabetic Nephropathy</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Hyperkalemia</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>324 participants were enrolled in the study; 306 participants were randomized to receive study drug.</recruitment_details>
      <pre_assignment_details>Screening serum potassium ≤ 5 mEq/L (milliequivalent) entered Run-in: Cohort 1 stopped ACEI/ARB (angiotensin-converting enzyme inhibitor/angiotensin receptor blockers), started losartan; Cohort 2 started spironolactone; Run-in (Cohorts 1 and 2) or screening (Cohort 3) &gt; 5 mEq/L entered study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Stratum 1</title>
          <description>Participants with baseline serum potassium &gt; 5.0 - 5.5 mEq/L are administered with 8.4 g/day, 16.8 g/day or 25.2 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
        </group>
        <group group_id="P2">
          <title>Stratum 2</title>
          <description>Participants with baseline serum potassium &gt; 5.5 - &lt; 6.0 mEq/L are administered 16.8 g/day, 25.2 g/day or 33.6 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="222"/>
                <participants group_id="P2" count="84"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Renal Function</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>High Serum Potassium Results</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Low Serum Potassium Results</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>306 participants were randomized and stratified by baseline serum potassium (2 randomized participants in Stratum 1 did not receive any study drug: 1 participant withdrew consent and 1 participant was randomized in error and was withdrawn from the study); 304 participants were analyzed for safety.</population>
      <group_list>
        <group group_id="B1">
          <title>Stratum 1</title>
          <description>Participants with baseline serum potassium &gt; 5.0 - 5.5 mEq/L are administered with 8.4 g/day, 16.8 g/day or 25.2 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
        </group>
        <group group_id="B2">
          <title>Stratum 2</title>
          <description>Participants with baseline serum potassium &gt; 5.5 - &lt; 6.0 mEq/L are administered with 16.8 g/day, 25.2 g/day or 33.6 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="220"/>
                <measurement group_id="B2" value="84"/>
                <measurement group_id="B3" value="304"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="85"/>
                <measurement group_id="B2" value="37"/>
                <measurement group_id="B3" value="122"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="135"/>
                <measurement group_id="B2" value="47"/>
                <measurement group_id="B3" value="182"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="68" lower_limit="37" upper_limit="80"/>
                <measurement group_id="B2" value="66.5" lower_limit="39" upper_limit="80"/>
                <measurement group_id="B3" value="67.5" lower_limit="37" upper_limit="80"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="81"/>
                <measurement group_id="B2" value="31"/>
                <measurement group_id="B3" value="112"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="139"/>
                <measurement group_id="B2" value="53"/>
                <measurement group_id="B3" value="192"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change in Serum Potassium From Baseline to Week 4 or Time of First Titration for Each Individual Starting Dose Group</title>
        <time_frame>Baseline to Week 4 or First Titration</time_frame>
        <safety_issue>No</safety_issue>
        <population>Included all randomized participants who received at least 1 dose of patiromer.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum 1</title>
            <description>Participants with baseline serum potassium &gt; 5.0 - 5.5 mEq/L are administered with 8.4 g/day, 16.8 g/day or 25.2 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Stratum 2</title>
            <description>Participants with baseline serum potassium &gt; 5.5 - &lt; 6.0 mEq/L are administered with 16.8 g/day, 25.2 g/day or 33.6 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="217"/>
                  <measurement group_id="O2" value="83"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change in Serum Potassium From Baseline to Week 4 or Time of First Titration for Each Individual Starting Dose Group</title>
            <units>mEq/L</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.47" spread="0.039"/>
                  <measurement group_id="O2" value="-0.92" spread="0.075"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Each starting dose group was compared to its baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-value &lt;0.001 for each starting dose group.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Each starting dose group was compared to its baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-Value &lt;0.001 for each starting dose group.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Serum Potassium From Baseline to Week 8 or Time of First Titration for Each Individual Starting Dose Group</title>
        <time_frame>Baseline to Week 8 or First Titration</time_frame>
        <safety_issue>No</safety_issue>
        <population>Included all randomized participants who received at least 1 dose of patiromer.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum 1</title>
            <description>Participants with baseline serum potassium &gt; 5.0 - 5.5 mEq/L are administered with 8.4 g/day, 16.8 g/day or 25.2 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Stratum 2</title>
            <description>Participants with baseline serum potassium &gt; 5.5 - &lt; 6.0 mEq/L are administered with 16.8 g/day, 25.2 g/day or 33.6 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="217"/>
                  <measurement group_id="O2" value="83"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change in Serum Potassium From Baseline to Week 8 or Time of First Titration for Each Individual Starting Dose Group</title>
            <units>mEq/L</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.45" spread="0.040"/>
                  <measurement group_id="O2" value="-0.91" spread="0.079"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Each starting dose group was compared to its baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-Value &lt;0.001 for each starting dose group.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Each starting dose group was compared to its baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-Value &lt;0.001 for each starting dose group.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Serum Potassium From Baseline to Day 3 During the Treatment Initiation Period for Each Individual Starting Dose Group</title>
        <time_frame>Baseline to Day 3</time_frame>
        <safety_issue>No</safety_issue>
        <population>Included all randomized participants who received at least 1 dose of patiromer.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum 1</title>
            <description>Participants with baseline serum potassium &gt; 5.0 - 5.5 mEq/L are administered with 8.4 g/day, 16.8 g/day or 25.2 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Stratum 2</title>
            <description>Participants with baseline serum potassium &gt; 5.5 - &lt; 6.0 mEq/L are administered with 16.8 g/day, 25.2 g/day or 33.6 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="200"/>
                  <measurement group_id="O2" value="81"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change in Serum Potassium From Baseline to Day 3 During the Treatment Initiation Period for Each Individual Starting Dose Group</title>
            <units>mEq/L</units>
            <param>Least Squares Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.29" spread="0.028"/>
                  <measurement group_id="O2" value="-0.59" spread="0.048"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Each starting dose group was compared to its baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-Value &lt;0.001 for each starting dose group.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Each starting dose group was compared to its baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>P-Value &lt;0.001 for each starting dose group.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Serum Potassium From Baseline to Week 52 During the Long-term Maintenance Period for Each Individual Starting Dose Group</title>
        <time_frame>Baseline to Week 52</time_frame>
        <safety_issue>No</safety_issue>
        <population>Included all randomized participants who received at least 1 dose of patiromer.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum 1</title>
            <description>Participants with baseline serum potassium &gt; 5.0 - 5.5 mEq/L are administered with 8.4 g/day, 16.8 g/day or 25.2 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Stratum 2</title>
            <description>Participants with baseline serum potassium &gt; 5.5 - &lt; 6.0 mEq/L are administered with 16.8 g/day, 25.2 g/day or 33.6 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="143"/>
                  <measurement group_id="O2" value="49"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change in Serum Potassium From Baseline to Week 52 During the Long-term Maintenance Period for Each Individual Starting Dose Group</title>
            <units>mEq/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.49" spread="0.441"/>
                  <measurement group_id="O2" value="-1.03" spread="0.480"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Each starting dose group was compared to its baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.49</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Each starting dose group was compared to its baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.03</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Serum Potassium From End of Treatment to Follow-up Visits Plus 7 Days</title>
        <time_frame>End of Treatment to Following up Visit Plus 7 Days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Included all randomized participants who received at least 1 dose of patiromer.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum 1</title>
            <description>Participants with baseline serum potassium &gt; 5.0 - 5.5 mEq/L are administered with 8.4 g/day, 16.8 g/day or 25.2 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Stratum 2</title>
            <description>Participants with baseline serum potassium &gt; 5.5 - &lt; 6.0 mEq/L are administered with 16.8 g/day, 25.2 g/day or 33.6 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="154"/>
                  <measurement group_id="O2" value="57"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Change in Serum Potassium From End of Treatment to Follow-up Visits Plus 7 Days</title>
            <units>mEq/L</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.29" spread="0.503"/>
                  <measurement group_id="O2" value="0.46" spread="0.540"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Each starting dose group was compared to its baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.29</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Each starting dose group was compared to its baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.46</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Achieving Serum Potassium Levels Within 3.5 to 5.5 mEq/L at Week 8 for Each Individual Starting Dose Group</title>
        <time_frame>Baseline to Week 8</time_frame>
        <safety_issue>No</safety_issue>
        <population>Included all randomized participants who received at least 1 dose of patiromer.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum 1</title>
            <description>Participants with baseline serum potassium &gt; 5.0 - 5.5 mEq/L are administered with 8.4 g/day, 16.8 g/day or 25.2 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Stratum 2</title>
            <description>Participants with baseline serum potassium &gt; 5.5 - &lt; 6.0 mEq/L are administered with 16.8 g/day, 25.2 g/day or 33.6 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="192"/>
                  <measurement group_id="O2" value="70"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Proportion of Participants Achieving Serum Potassium Levels Within 3.5 to 5.5 mEq/L at Week 8 for Each Individual Starting Dose Group</title>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="99.5" lower_limit="97.1" upper_limit="100.0"/>
                  <measurement group_id="O2" value="94.3" lower_limit="86.0" upper_limit="98.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Each starting dose group was compared to its baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>2-sided 95% exact binomial CI</param_type>
            <param_value>99.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.1</ci_lower_limit>
            <ci_upper_limit>100.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Each starting dose group was compared to its baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>2-sided 95% exact binomial Cl</param_type>
            <param_value>94.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.0</ci_lower_limit>
            <ci_upper_limit>98.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants Achieving Serum Potassium Levels Within 4.0 to 5.0 mEq/L at Week 8 for Each Individual Starting Dose Group</title>
        <time_frame>Baseline to Week 8</time_frame>
        <safety_issue>No</safety_issue>
        <population>Included all randomized participants who received at least 1 dose of patiromer.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum 1</title>
            <description>Participants with baseline serum potassium &gt; 5.0 - 5.5 mEq/L are administered with 8.4 g/day, 16.8 g/day or 25.2 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Stratum 2</title>
            <description>Participants with baseline serum potassium &gt; 5.5 - &lt; 6.0 mEq/L are administered with 16.8 g/day, 25.2 g/day or 33.6 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="192"/>
                  <measurement group_id="O2" value="70"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Proportion of Participants Achieving Serum Potassium Levels Within 4.0 to 5.0 mEq/L at Week 8 for Each Individual Starting Dose Group</title>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="89.1" lower_limit="83.8" upper_limit="93.1"/>
                  <measurement group_id="O2" value="82.9" lower_limit="72.0" upper_limit="90.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Each starting dose group was compared to its baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>2-sided 95% exact binomial CI</param_type>
            <param_value>89.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>83.8</ci_lower_limit>
            <ci_upper_limit>93.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Each starting dose group was compared to its baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>2-sided 95% exact binomial CI</param_type>
            <param_value>82.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>72.0</ci_lower_limit>
            <ci_upper_limit>90.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Serum Potassium Measurement of 4.0 - 5.0 mEq/L During Treatment Initiation Period for Each Individual Starting Dose Group</title>
        <time_frame>Baseline to Week 8</time_frame>
        <safety_issue>No</safety_issue>
        <population>Included all randomized participants who received at least 1 dose of patiromer.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum 1</title>
            <description>Participants with baseline serum potassium &gt; 5.0 - 5.5 mEq/L are administered with 8.4 g/day, 16.8 g/day or 25.2 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Stratum 2</title>
            <description>Participants with baseline serum potassium &gt; 5.5 - &lt; 6.0 mEq/L are administered with 16.8 g/day, 25.2 g/day or 33.6 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="217"/>
                  <measurement group_id="O2" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time to First Serum Potassium Measurement of 4.0 - 5.0 mEq/L During Treatment Initiation Period for Each Individual Starting Dose Group</title>
            <units>Days</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="4">NA = not achieved</measurement>
                  <measurement group_id="O2" value="8" lower_limit="4" upper_limit="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportions of Participants Achieving Serum Potassium Levels Within 3.8 to 5.0 mEq/L at Week 52 for Each Individual Starting Dose Group</title>
        <time_frame>Baseline to Week 52</time_frame>
        <safety_issue>No</safety_issue>
        <population>Included all randomized participants who received at least 1 dose of patiromer.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratum 1</title>
            <description>Participants with baseline serum potassium &gt; 5.0 - 5.5 mEq/L are administered with 8.4 g/day, 16.8 g/day or 25.2 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
          </group>
          <group group_id="O2">
            <title>Stratum 2</title>
            <description>Participants with baseline serum potassium &gt; 5.5 - &lt; 6.0 mEq/L are administered with 16.8 g/day, 25.2 g/day or 33.6 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="145"/>
                  <measurement group_id="O2" value="49"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Proportions of Participants Achieving Serum Potassium Levels Within 3.8 to 5.0 mEq/L at Week 52 for Each Individual Starting Dose Group</title>
            <units>percentage of participants</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="85.5" lower_limit="78.7" upper_limit="90.8"/>
                  <measurement group_id="O2" value="89.8" lower_limit="77.8" upper_limit="96.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Each starting dose group was compared to its baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>2-sided 95% exact binomial CI</param_type>
            <param_value>85.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>78.7</ci_lower_limit>
            <ci_upper_limit>90.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Each starting dose group was compared to its baseline.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>2-sided 95% exact binomial CI</param_type>
            <param_value>89.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>77.8</ci_lower_limit>
            <ci_upper_limit>96.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 28 days after end of treatment</time_frame>
      <desc>Randomized participants who received at least one dose of trial medication</desc>
      <group_list>
        <group group_id="E1">
          <title>Stratum 1</title>
          <description>Participants with baseline serum potassium &gt; 5.0 - 5.5 mEq/L are administered with 8.4 g/day, 16.8 g/day or 25.2 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
        </group>
        <group group_id="E2">
          <title>Stratum 2</title>
          <description>Participants with baseline serum potassium &gt; 5.5 - &lt; 6.0 mEq/L are administered with 16.8 g/day, 25.2 g/day or 33.6 g/day patiromer starting dose, orally, as a divided dose twice a day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Mesenteric artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Brain death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Arteriosclerotic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="220"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="84"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Our agreements generally provide that PI cannot publish single site data before publication of the multi-site publication, unless 1 year has elapsed since completion of the study at all sites. Thereafter, PI may publish provided that PI shall: provide a copy of the publication to sponsor at least 60 days in advance of submission for publication; delete sponsor’s confidential information as requested; and delay publication up to an additional 90 days to permit protection of intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information</name_or_title>
      <organization>Relypsa, Inc.</organization>
      <phone>1-844-relypsa</phone>
      <email>medinfo@relypsa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
